These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17593551)

  • 1. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats.
    Hassan HE; Myers AL; Lee IJ; Coop A; Eddington ND
    J Pharm Sci; 2007 Sep; 96(9):2494-506. PubMed ID: 17593551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833.
    Boström E; Simonsson US; Hammarlund-Udenaes M
    J Pharm Sci; 2005 May; 94(5):1060-6. PubMed ID: 15799017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
    Panchagnula R; Bansal T; Varma MV; Kaul CL
    Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
    Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
    Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
    Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
    Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
    Fujii S; Setoguchi C; Kawazu K; Hosoya K
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
    Kemper EM; Cleypool C; Boogerd W; Beijnen JH; van Tellingen O
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):173-8. PubMed ID: 14605863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.
    Hassan HE; Myers AL; Coop A; Eddington ND
    J Pharm Sci; 2009 Dec; 98(12):4928-40. PubMed ID: 19370547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
    Kalvass JC; Olson ER; Pollack GM
    Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
    Ohashi R; Kamikozawa Y; Sugiura M; Fukuda H; Yabuuchi H; Tamai I
    Drug Metab Dispos; 2006 May; 34(5):793-9. PubMed ID: 16455807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
    Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents.
    Salama NN; Scott KR; Eddington ND
    Int J Pharm; 2004 Apr; 273(1-2):135-47. PubMed ID: 15010138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats.
    Cai Q; Deng X; Li Z; An D; Shen T; Zhong M
    Drug Deliv; 2016; 23(1):147-53. PubMed ID: 24786483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats.
    Nielsen CU; Abdulhussein AA; Colak D; Holm R
    Int J Pharm; 2016 Nov; 513(1-2):78-87. PubMed ID: 27601334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
    Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
    Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
    Zhang J; Zhou F; Wu X; Gu Y; Ai H; Zheng Y; Li Y; Zhang X; Hao G; Sun J; Peng Y; Wang G
    Drug Metab Dispos; 2010 Dec; 38(12):2179-87. PubMed ID: 20837659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
    Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trantinterol, a novel β2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein function in vitro and in vivo.
    Wang T; Sun Y; Ma W; Yang Z; Yang J; Liu J; Fan H; Yang Y; Gu J; Fawcett JP; Guo Y
    Mol Pharm; 2015 Jan; 12(1):1-9. PubMed ID: 25389765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
    Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
    J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
    Eriksson UG; Dorani H; Karlsson J; Fritsch H; Hoffmann KJ; Olsson L; Sarich TC; Wall U; Schützer KM
    Drug Metab Dispos; 2006 May; 34(5):775-82. PubMed ID: 16455803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.